PROTRACT: A randomized phase II trial comparing ctDNA-guided biomarker directed therapy vs patient/clinician’s choice for metastatic castration resistant prostate cancer (mCRPC) progressing after abiraterone plus prednisone (AAP).

Journal of Clinical Oncology 2026 Open access

Read full text
Authors: Corinne Maurice-Dror, Karan Parekh, Simon Yuen Fai Fu, Kamal Al Najem Azzam, Joanna Vergidis, Krista L. Noonan, Daygen L. Finch, Urban Emmenegger, Jesse Shustik, Daniel Joseph Khalaf, Christian Kollmannsberger, Lucia Nappi
+7 more Maryam Soleimani, Martin Smoragiewicz, Andrew J. Murtha, Cecily Q. Bernales, Matti Annala, Alexander William Wyatt, Kim N. Chi
DOI: 10.1200/jco.2026.44.16_suppl.5017
Cited by: 1

Abstract

5017 Background: A subset of mCRPC patients (pts) will benefit from enzalutamide (ENZA) following disease progression on AAP. Preliminary data suggests that higher plasma ctDNA/total cfDNA fraction (ctDNA%) post-AAP predicts poor response to ENZA but preserved sensitivity to docetaxel (DOC). We hypothesize that ctDNA%-guided selection of enzalutamide or docetaxel in chemotherapy-naïve mCRPC post-abiraterone will improve clinical outcomes versus patient/clinician’s choice of treatment. Methods: A multi-centre, open-label, phase II trial randomized mCRPC pts progressing after AAP 1:1 to biomarker-directed therapy (Arm A: ctDNA% ≥2% receives DOC; ctDNA%

Fields of Study & Subjects

Prostate Cancer Treatment and Research Cancer Genomics and Diagnostics PARP inhibition in cancer therapy

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
16_suppl
Pages
5017–5017
Publication date
27 May 2026
Language
EN